Extensive AAV and lentiviral vector production capabilities & expertise
Yposkesi is a full-service CDMO, providing professional support through all stages of gene therapy development. We make available the entire viral vector manufacturing services necessary to enable you to rapidly and successfully develop ATMPs. You gain access to specialized expertise with integrated project management as well as streamlined and cost-efficient bioprocess development services:
GMP manufacturing of clinical & commercial batches
Yposkesi has four independent GMP manufacturing suites where we perform either adherent (24CF10) or suspension (up to 2*200L single use bioreactors) process. Those suites are spacious enough to accommodate the installation of additional specific equipment, such as large size single use bioreactors (up to 500L) or additional chromatography steps. They are grade C and are operated at Biosafety level 2. Typical purification steps performed in these GMP areas cover depth filtration, tangential flow filtration, chromatography (affinity, ion-exchange, size exclusion).
The facility has an operational capacity of up to 33 batches per year.
Yposkesi is extending this capacity. By 2022 it will double its global footprint to 100,000 sq ft (approx. 10,000m2) with a second large-scale facility designed for commercial production and EMA and FDA compliance. Yposkesi invests significantly in innovation and bioprocessing to deliver on high quality projects, cost-effectively.